Umoja Biopharma Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 195

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $100M

  • Investors
  • 24

Umoja Biopharma General Information

Description

Operator of a biotechnology platform designed to advance a novel approach to cancer immunotherapy by generating engineered immune cells. The company's platform offers integrated gene delivery technology, in-house lentiviral vector development, and a pipeline of in vivo cell therapies, enabling clinical researchers to pursue treatments that may reach more patients with improved accessibility and immune system-based control compared to conventional methods.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1150 Eastlake Avenue East
  • Suite 400
  • Seattle, WA 98109
  • United States
+1 (206)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 1150 Eastlake Avenue East
  • Suite 400
  • Seattle, WA 98109
  • United States
+1 (206)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Umoja Biopharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 19-Jan-2025 $100M Completed Pre-Clinical Trials
3. Early Stage VC (Series B) 15-Jun-2021 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 18-Nov-2020 $53M $61M Completed Pre-Clinical Trials
1. Seed Round 21-Nov-2019 $8M $8M Completed Pre-Clinical Trials
To view Umoja Biopharma’s complete valuation and funding history, request access »

Umoja Biopharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B-1
Series B
Series A-2
Series A-1
Series A
Seed 1 565,996 $0.000100 $2.24 $2.24 1x $2 0.6%
Seed 2,400,773 $0.000100 $2.8 $2.8 1x $2.25 2.81%
To view Umoja Biopharma’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Umoja Biopharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology platform designed to advance a novel approach to cancer immunotherapy by generating engineer
Drug Discovery
Seattle, WA
195 As of 2025

Abingdon, United Kingdom
 

King of Prussia, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Umoja Biopharma Competitors (63)

One of Umoja Biopharma’s 63 competitors is Adaptimmune Therapeutics, a Formerly VC-backed company based in Abingdon, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Phio Pharmaceuticals Formerly Accelerator/Incubator backed King of Prussia, PA
TME Pharma Formerly VC-backed Berlin, Germany
Cellaion Formerly VC-backed Mont-Saint-Guibert, Belgium
Xenetic Biosciences Corporation Framingham, MA
You’re viewing 5 of 63 competitors. Get the full list »

Umoja Biopharma Patents

Umoja Biopharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026143070-A1 Improved rapamycin activated synthetic receptor transgene constructs Pending 23-Dec-2024
WO-2026143065-A1 Polynucleotide construct for chimeric antigen receptor expression and related viral vectors and methods Pending 23-Dec-2024
WO-2026136737-A1 Cd58-pseudotyped viral particles and uses thereof Pending 19-Dec-2024
WO-2026123000-A2 Cytokine armored engineered innate lymphoid cells and related methods Pending 06-Dec-2024
WO-2026123000-A3 Cytokine armored engineered innate lymphoid cells and related methods Pending 06-Dec-2024 C12N5/0647
To view Umoja Biopharma’s complete patent history, request access »

Umoja Biopharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Umoja Biopharma Investors (24)

Investor Name Investor Type Holding Investor Since Participating Rounds
ARK Ventures (US) Venture Capital Minority
Double Point Ventures Venture Capital Minority
K2 HealthVentures Venture Capital Minority
Myeloma Investment Fund Not-For-Profit Venture Capital Minority
Realm Capital Ventures Venture Capital Minority
You’re viewing 5 of 24 investors. Get the full list »

Umoja Biopharma FAQs

  • When was Umoja Biopharma founded?

    Umoja Biopharma was founded in 2019.

  • Where is Umoja Biopharma headquartered?

    Umoja Biopharma is headquartered in Seattle, WA.

  • What is the size of Umoja Biopharma?

    Umoja Biopharma has 195 total employees.

  • What industry is Umoja Biopharma in?

    Umoja Biopharma’s primary industry is Drug Discovery.

  • Is Umoja Biopharma a private or public company?

    Umoja Biopharma is a Private company.

  • What is the current valuation of Umoja Biopharma?

    The current valuation of Umoja Biopharma is .

  • What is Umoja Biopharma’s current revenue?

    The current revenue for Umoja Biopharma is .

  • How much funding has Umoja Biopharma raised over time?

    Umoja Biopharma has raised $371M.

  • Who are Umoja Biopharma’s investors?

    ARK Ventures (US), Double Point Ventures, K2 HealthVentures, Myeloma Investment Fund, and Realm Capital Ventures are 5 of 24 investors who have invested in Umoja Biopharma.

  • Who are Umoja Biopharma’s competitors?

    Adaptimmune Therapeutics, Phio Pharmaceuticals, TME Pharma, Cellaion, and Xenetic Biosciences are some of the 63 competitors of Umoja Biopharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process